5 results on '"West, Natalie E."'
Search Results
2. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
- Author
-
Thornton, Christina S., Caverly, Lindsay J., Kalikin, Linda M., Carmody, Lisa A., McClellan, Scott, LeBar, William, Sanders, Don B., West, Natalie E., Goss, Christopher H., Flume, Patrick A., Heltshe, Sonya L., VanDevanter, Donald R., and LiPuma, John J.
- Subjects
PULMONARY fibrosis ,CYSTIC fibrosis ,RESPIRATORY infections ,VIRUS diseases ,BURKHOLDERIA infections ,FORCED expiratory volume ,PSEUDOMONAS aeruginosa infections - Abstract
Rationale: Rates of viral respiratory infection (VRI) are similar in people with cystic fibrosis (CF) and the general population; however, the associations between VRI and CF pulmonary exacerbations (PEx) require further elucidation. Objectives: To determine VRI prevalence during CF PEx and evaluate associations between VRI, clinical presentation, and treatment response. Methods: The STOP2 (Standardized Treatment of Pulmonary Exacerbations II) study was a multicenter randomized trial to evaluate different durations of intravenous antibiotic therapy for PEx. In this ancillary study, participant sputum samples from up to three study visits were tested for respiratory viruses using multiplex polymerase chain reactions. Baselines and treatment-associated changes in mean lung function (percent predicted forced expiratory volume in 1 s)
, respiratory symptoms (Chronic Respiratory Infection Symptom Score), weight, and C-reactive protein were compared as a function of virus detection. Odds of PEx retreatment within 30 days and future PEx hazard were modeled by logistic and Cox proportional hazards regression, respectively. Results: A total of 1,254 sputum samples from 621 study participants were analyzed. One or more respiratory viruses were detected in sputum samples from 245 participants (39.5%). Virus-positive participants were more likely to be receiving CF transmembrane conductance regulator modulator therapy (45% vs. 34%) and/or chronic azithromycin therapy (54% vs. 44%) and more likely to have received treatment for nontuberculous Mycobacterium infection in the preceding 2 years (7% vs. 3%). At study visit 1, virus-positive participants were more symptomatic (mean Chronic Respiratory Infection Symptom Score, 53.8 vs. 51.1), had evidence of greater systemic inflammation (log10 C-reactive protein concentration, 1.32 log10 mg/L vs. 1.23 log10 mg/L), and had a greater drop in percent predicted forced expiratory volume in 1 second from the prior 6-month baseline (5.8 vs. 3.6). Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69–0.99; P = 0.034) and longer median time to next PEx (255 d vs. 172 d; P = 0.021) compared with virus negativity. Conclusions: More than one-third of STOP2 participants treated for a PEx had a positive test result for a respiratory virus with more symptomatic initial presentation compared with virus-negative participants, but favorable long-term outcomes. More refined phenotyping of PEx, taking VRIs into account, may aid in optimizing personalized management of PEx. Clinical trial registered with www.clinicaltrials.gov (NCT 02781610). [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.
- Author
-
Gold, Laura S., Hansen, Ryan N., Patrick, Donald L., Tabah, Ashley, Heltshe, Sonya L., Flume, Patrick A., Goss, Christopher H., West, Natalie E., Sanders, Don B., VanDevanter, Donald R., and Kessler, Larry
- Subjects
- *
MEDICAL care costs , *PULMONARY fibrosis , *CYSTIC fibrosis , *DISEASE exacerbation , *TREATMENT duration , *EMERGENCY nursing - Abstract
Pulmonary exacerbations are clinically debilitating and expensive to treat. Ideal duration of treatment with antimicrobial medication is unknown. Clinical outcomes (lung function) were similar between treatment duration groups. Thirty-day costs were lower in groups that were randomized to receive IV treatment for shorter durations. The purpose of these analyses was to determine whether overall costs were reduced in cystic fibrosis (CF) patients experiencing pulmonary exacerbation (PEx) who received shorter versus longer durations of treatment. Among people with CF experiencing PEx, we calculated 30-day inpatient, outpatient, emergency room, and medication costs and summed these to derive total costs in 2020 USD. Using the Kaplan-Meier sample average (KMSA) method, we calculated adjusted costs and differences in costs within two pairs of randomized groups: early robust responders (ERR) randomized to receive treatment for 10 days (ERR-10 days) or 14 days (ERR-14 days), and non-early robust responders (NERR) randomized to receive treatment for 14 days (NERR-14 days) or 21 days (NERR-21 days). Patients in the shorter treatment duration groups had shorter lengths of stay per hospitalization (mean ± standard deviation (SD) for ERR-10 days: 7.9 ± 3.0 days per hospitalization compared to 10.1 ± 4.2 days in ERR-14 days; for NERR-14 days: 8.7 ± 4.9 days per hospitalization compared to 9.6 ± 6.5 days in NERR-21 days). We found statistically significantly lower adjusted mean costs (95% confidence interval) among those who were randomized to receive shorter treatment durations (ERR-10 days: $60,800 ($59,150 - $62,430) vs $74,420 ($72,610 - $76,450) in ERR-14 days; NERR-14 days: $66,690 ($65,960-$67,400) versus $74,830 ($73,980-$75,650) in NERR-21 days). Tied with earlier evidence that shorter treatment duration was not associated with worse clinical outcomes, our analyses indicate that treating with shorter antimicrobial durations can reduce costs without diminishing clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations.
- Author
-
Montemayor, Kristina, Psoter, Kevin J., Lechtzin, Noah, Carson, Sara W., Merlo, Christian A., Dezube, Rebecca H., Riekert, Kristin A., Allgood, Sarah, Toporek, Alexandra, Jennings, Mark T., and West, Natalie E.
- Subjects
- *
PULMONARY fibrosis , *CYSTIC fibrosis , *LENGTH of stay in hospitals , *DISEASE exacerbation , *TREATMENT effectiveness - Abstract
• Females with CF have been reported to have worse pulmonary exacerbation (PEx) related outcomes compared to males. • Females were treated with IV antibiotics 1.6 days longer on average compared to males. • We found no sex differences in regards to inpatient length of stay, IV antibiotic selections or adjunctive therapies. • Females reported worse respiratory symptoms at the end of IV therapy despite receiving similar PEx treatment. • Future sex differences research in people with CF is needed. Females with cystic fibrosis (CF) have been shown to have worse pulmonary exacerbation (PEx) related outcomes compared to males. However, it is unknown if sex differences in treatment patterns are contributing to these outcomes. Thus, we sought to explore sex differences in treatment patterns in the Standardized Treatment of Pulmonary Exacerbations (STOP) cohort. Data for 220 participants from the STOP cohort were analyzed. Multivariable regression models were used to assess if female sex was associated with duration of treatment with IV antibiotics and inpatient length of stay. Secondary outcomes included antibiotic selection, adjunctive therapies, mean FEV1pp and CFRSD-CRISS respiratory symptom scores at the four study assessments. In our adjusted model, the average number of IV antibiotic treatment days was 13% higher in females compared to males (IRR 1.13, 95% CI=1.02,1.25; p=0.02). We found no sex differences in inpatient length of stay, number of IV antibiotics, antibiotic selection or initiation of adjunctive therapies. Overall, females had higher CFRSD-CRISS scores at the end of IV therapy indicating worse symptom severity (23.6 for females vs. 18.5 for males, p=0.03). Despite females having a longer treatment duration, our findings demonstrate that males and females are receiving similar treatments which suggest that the outcome disparities in females with CF may not be due to failure to provide the same level of care. Further research dedicated to sex differences in CF is necessary to understand why clinical outcomes differ between males and females. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis.
- Author
-
Taylor-Cousar, Jennifer L., Jain, Raksha, Kazmerski, Tracy M., Aitken, Moira L., West, Natalie E., Wilson, Alexandra, Middleton, Peter G., and Nash, Edward F.
- Subjects
- *
CYSTIC fibrosis , *AZITHROMYCIN , *LEUCOCYTES , *PULMONARY fibrosis , *TREATMENT effectiveness , *PREGNANCY - Abstract
• Chronic azithromycin (AZM) is used for treatment of pulmonary disease in CF. • Macrolide use is associated with no risk to a small increased risk of congenital malformations. • AZM has a prolonged half-life in white blood cells. • Risk to the mother of AZM discontinuation must be weighed against potential risk to the fetus. Chronic oral azithromycin therapy improves clinical outcomes in people with cystic fibrosis (CF), and is recommended for treatment of CF lung disease. Azithromycin is categorized as pregnancy class B. The data for risk of congenital malformations associated with use of azithromycin during pregnancy ranges from no risk to a small increased risk. As with other chronic medications used to treat CF, potential risk to the infant of use of azithromycin during pregnancy must be weighed against the potential risk to the mother of treatment discontinuation. Women with CF considering pregnancy while on chronic azithromycin should be counseled regarding potential risks and benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.